IHCH-8110 is a peripherally selective and non-hallucinogenic serotonin 5-HT2A receptor agonist.
Pharmacology IHCH-8110 shows affinity for the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors (Ki = 48nM, 102nM, and 302nM, respectively). The drug is a partial agonist at the serotonin 5-HT2A receptor with an of 93–479nM and of 45–68%. It is also a partial agonist of the serotonin 5-HT2C receptor but not of the serotonin 5-HT2B receptor, where it instead functioned as an antagonist. The drug did not interact with other serotonin or dopamine receptors.
IHCH-8110 is highly peripherally selective and does not produce the head-twitch response, a behavioral proxy of psychedelic effects, nor affect locomotor activity in rodents. It has been found to enhance CD8+ T cell-mediated antitumor immunity and inflammation and to suppress colorectal cancer progression, effects mediated by activation of serotonin 5-HT2A receptors on enteric glial cells that results in increased CXCL10 and interleukin-18 expression.
Chemistry The chemical synthesis of IHCH-8110 has been described.
History IHCH-8110 was first described in the scientific literature by YaTing Wen and colleagues in 2026. It was developed following observations of the psychedelic drug LSD having similar colonic effects. There is interest in IHCH-8110 for potential medical use in colorectal cancer immunotherapy.
See also IHCH-6122 Serotonin 5-HT2A receptor agonist List of miscellaneous 5-HT2A receptor agonists
References